Does the 13-valent pneumococcal vaccine prevent mycoplasma pneumonia?

The full name of 13-valent pneumococcal polysaccharide conjugate vaccine is 13-valent pneumococcal polysaccharide conjugate vaccine, and 13-valent pneumococcal polysaccharide conjugate vaccine cannot prevent mycoplasma pneumonia.

13-valent pneumococcal polysaccharide conjugate vaccine contains 13 serotypes of pneumococcal capsular polysaccharide bound to carrier proteins, which can be used to prevent acute otitis media, pneumonia, meningitis,Bacteraemiaand sinusitis and other pneumococcal diseases, because mycoplasma and pneumococcus are two completely different pathogens, so there is no preventive effect on mycoplasma pneumonia.

The 13-valent pneumococcal polysaccharide conjugate vaccine is suitable for children aged 6 weeks to 5 years, and people with a history of allergic reactions or severe allergic reactions to any component of this vaccine should not receive this vaccine, and individuals with fever, acute illness and active chronic disease (such as acute and chronic hepatitis) are recommended to be vaccinated only after their condition is stable.

Adverse reactions such as fever, diarrhea, and vomiting may occur in vaccinated patients, and it is recommended that the 13-valent pneumococcal polysaccharide conjugate vaccine should be carried out under the guidance of a doctor, and adverse reactions such as fever should be informed to the doctor in time after vaccination.